HeBA study adds NeuraLight eye-movement biomarkers to track early brain changes

The Healthy Brain Ageing (HeBA) initiative is integrating NeuraLight’s eye-movement biomarkers into its large European study investigating early changes associated with neurodegenerative disorders, with a particular focus on Parkinson’s disease. The collaboration will add a scalable measure of brain function to a programme involving nearly 13,000 adults aged 50 to 80.

HeBA operates across Germany, Austria, Spain and Luxembourg and is supported by The Michael J. Fox Foundation. The initiative aims to improve the identification of people at increased risk of developing Parkinson’s disease before a clinical diagnosis, including during the prodromal phase when symptoms may be absent or subtle.

NeuraLight’s technology uses a 10-minute eye-movement assessment to quantify aspects of brain function. Eye movements are controlled by distributed neural networks, and the company’s biomarkers are designed to measure changes in specific neural circuits, including those that may be affected during ageing and neurodegenerative disease.

| Join 2,500 ACNR email subscribers |

The biomarkers will be incorporated alongside the biological and clinical assessments already used by HeBA. Researchers hope the additional measurements will help identify and track subtle functional changes over time that may not yet be apparent through conventional clinical assessment.

The approach has previously been evaluated in a peer-reviewed study published in Pharmaceutical Medicine. That research assessed eye-movement biomarkers for monitoring Parkinson’s disease progression and reported sensitivity to change over a nine-month period.

HeBA recruits adults without a neurodegenerative diagnosis and uses online assessments to identify participants who may benefit from further investigation. Selected participants are offered in-person evaluation and prospective follow-up.

The collaboration could provide researchers with additional longitudinal data on how measurable brain function changes before and during the emergence of neurodegenerative disease, potentially supporting the development of earlier detection and monitoring approaches.

This news item has been summarised using AI and checked by humans before publication.

| Join our online community for neurology specialists |


Sources

https://www.businesswire.com/news/home/20260813008681/en/Landmark-International-Brain-Health-Initiative-Deploys-NeuraLights-Biomarkers-to-Quantify-Change-in-Brain-Function

https://ageinghealthy.eu/